Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...

The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This is an ASCO Meeting Abstract from the ...